Remove tag share-pricing
article thumbnail

STAT+: Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy

STAT

Kyowa Kirin is paying $16 per share — a nearly 100% premium on Orchard’s Wednesday closing price — in cash, amounting to roughly $390 million. LONDON — The Japanese firm Kyowa Kirin is acquiring gene therapy maker Orchard Therapeutics in a $400 million deal, the companies said Thursday.

95
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

FDA 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Axsome bounces back as FDA clears depression drug

pharmaphorum

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator.

FDA 97
article thumbnail

Second unanimous FDA adcomm vote boosts bluebird bio

pharmaphorum

Trading in bluebird’s shares was suspended during the two-day meeting, and the positive outcome suggests the stock may rise when it resumes on Monday, and firm up confidence in other gene therapy stocks after a tumultuous couple of years in which safety has been thrust into the spotlight.

FDA 58
article thumbnail

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

“Transformative, lifesaving products are available at increasingly high and unsustainable prices. This evolution is leading to additional health benefits and health gains, but they are accompanied by major concerns, as very high price tags raise questions about their affordability.”. WHO is OMI? Finding solutions.

article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). Since the price of the therapies is unknown, the institute used a placeholder cost of $2 million.

FDA 59
article thumbnail

Biogen’s Aduhelm rollout goes from bad to worse

pharmaphorum

Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug. Many are still predicting multibillion-dollar sales for the drug, albeit with a longer runway, despite reservations about its clinical efficacy among doctors and payers.

Insurance 117